Compounds

Compound Name Developer(s)
1599 Microbiotix, Inc.
2HRZE 2HR
Actinomycete metabolites
Adamantanids
Alpibectir (BVL-GSK098) BioVersys AG, GlaxoSmithKline
Amidino-urea 8918 Weill Medical College of Cornell University, NIAID, NIH, DHHS
ATP Synthesis Inhibitors TB Alliance, University of Auckland
Auranofin The Aurum Institute NPC, Calibr, The Scripps Research Institute
AZD5847 AstraZeneca
Bedaquiline Janssen Research & Development, LLC
Benzofuroxan São Paulo State University (UNESP)
Bi-functional Molecules
Bortezomib SPRINT TB (National University of Singapore)
BRD4592 The Broad Institute
BTZ-043 University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
CC-11050 The Aurum Institute NPC, Medicines Development for Global Health
Celecoxib
Celecoxib WBA
CLB073 Bill & Melinda Gates Medical Research Institute
Clofazimine Novartis
Contezolid (MRX-4/MRX-1) MicuRx Pharmaceuticals, Inc.
CPZEN-45
Cyclopeptides
DC-159a
Delamanid Otsuka Pharmaceutical Development & Commercialization, Inc.
Delpazolid (LCB01-0371) LegoChem Biosciences, Inc.
DNA metabolism
DprE Inhibitors
DprE1 Inhibitors Calibr, The Scripps Research Institute
EMB
Energy Metabolism Inhibitors
Everolimus The Aurum Institute NPC
Faropenem WBA
FNDR 20364
FNDR-20081 Foundation for Neglected Disease Research
Folate Biosynthesis Inhibitors
Ganfeborole (GSK 3036656) GlaxoSmithKline, European Union Horizon 2020, NIAID, NIH, DHHS
Gatifloxacin
GSK 724A (DG167) GlaxoSmithKline, Rutgers, The State University of New Jersey
GSK-286 GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
GSK-693
GSK839 GlaxoSmithKline
GSK839 GlaxoSmithKline
Gyrase B Inhibitor
GyrB Inhibitors
HE2000
HMG-CoA Reductase Inhibitors
Hsp65 DNA
Imatinib
Immunoxel
IMPDH Inosine monophosphate dehydrogenase inhibitors
Indazoles GlaxoSmithKline, TB Alliance
Indolcarboxamides TB Alliance
Indoles
Inhibitors of DosRST signaling and persistence Michigan State University
Inhibitors of isoprenoid biosynthesis
Isoniazid
JSF-3285
LeuRS inhibitors GlaxoSmithKline, Anacor Pharmaceuticals
Levofloxacin CDC TBTC, NIAID, NIH, DHHS, Boston University
Linezolid
Macozinone (MCZ, PBTZ-169) Nearmedic Plus LLC
Macozinone (MCZ, PBTZ-169) iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Macrolides
Malate Synthase Inhibitors
MBX-4888A Microbiotix, Inc.
Menaquinone Synthase Inhibitors
Meropenem / Clavulanate
Metformin
Moxifloxacin TB Alliance
Moxifloxacin for Drug-Sensitive TB
MTopo
Mycobacterial Gyrase Inhibitors
Nitazoxanide Weill Medical College of Cornell University
Novel hit-lead programs
NTB-3119 Institute of Materia Medica
Optimized Background Regimen (OBR)
OTB-658 Institute of Materia Medica, CAMS & PUMC
Phenotypic Hit-to-Lead
PKS13 Inhibitors - Coumestan Derivatives
PKS13 Inhibitors - TAM16
Pravastatin NIAID, NIH, DHHS
Pretomanid TB Alliance
Protein Splicing Inhibitors
Pyrazinamide
Pyrazinamide Analogs
Pyridomycin
Quabodepistat (OPC-167832) Otsuka Pharmaceutical Development & Commercialization, Inc.
Quinolone TBK-613
Rifabutin
Rifafour
Rifampicin PanACEA, EDCTP, NIAID, NIH, DHHS, USAID
Rifapentine CDC TBTC, Sanofi
RNA Polymerase Inhibitors
Ruthenium (II) phosphine/diimine/picolinate complexes
S-004992 Shionogi & Co., Ltd
Sanfetrinem GlaxoSmithKline, Bill & Melinda Gates Foundation
SATB-082 Sanofi, TB Alliance
SPR-113
SPR720 (Fobrepodacin) Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute
SQ109 Sequella, Inc
SQ609 Sequella, Inc
SQ641
Sudapyridine (WX-081) Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China
Sulfolane GlaxoSmithKline
Sutezolid Sequella, Inc, TB Alliance
TB Respiratory Chain CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson
TB47 Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
TBA-354 TB Alliance
TBA-7371 TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research
TBAJ-587, Diarylquinoline TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc.
TBAJ-876 TB Alliance, University of Auckland
TBD09 (MK7762) Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc., NIAID, NIH, DHHS
TBI-166 Institute of Materia Medica, CAMS & PUMC
TBI-223 TB Alliance, Institute of Materia Medica
Telacebec (Q203) Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
TGF-B inhib +Cox 2 inhibitor
Thioridazine
TL1 Inhibitors
Trisubstituted benzimidazoles
Tryptanthrins
TZY-5-84
Ureas
Vitamin B6
Vitamin D3 The Aurum Institute NPC
Whole cell fragment screens
Whole Cell Hit-to Lead
Whole cell pathway screens
Whole-Cell Hit-to-Lead
Xanthones